DOCSLIB.ORG

Controlled Substance Conversion Factors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Controlled Substance Conversion Factors SCHEDULES I - V CONTROLLED SUBSTANCE CONVERSION FACTORS Drug Conversion Controlled Substance Schedule Code Factor (+/-)cis -4-Methylaminorex I 1590 1.00 (+/-)cis -4-Methylaminorex Hydrochloride I 1590 0.83 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (ethylone) I 7547 1.00 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (ethylone) hydrochloride I 7547 0.86 (1-(4-fluorobenzyl)-1H -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144) I 7014 1.00 1-(4-cyanobutyl)-N -(2-phenylpropan-2-yl)-1H -indazole-3-carboxamide (4-CN-CUMYL-BUTINACA) I 7089 1.00 1-(5-fluoropentyl)-1H -indazol-3-yl](naphthalen-1-yl)methanone (THJ–2201) 1 7024 1.00 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201) I 7201 1.00 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) I 7694 1.00 1-(5-fluoropentyl)-N -(2-phenylpropan-2-yl)-1H -indazole-3-carboxamide (5F-CUMYL-PINACA; SGT-25) I 7083 1.00 1-(5-fluoropentyl)-N -(2-phenylpropan-2-yl)-1H -pyrrolo[2,3-b]pyridine-3-carboxamide (5F-CUMYL-P7AICA) I 7085 1.00 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (TCPy) I 7473 1.00 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 200) I 7200 1.00 1-butyl-3-(1-naphthoyl)indole (JWH-073) I 7173 1.00 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) I 9560 1.00 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine hydrochloride (MT-45) I 9560 0.91 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole 7008 (SR-18 and RCS-8) I 7008 1.00 1-hexyl-3-(1-naphthoyl)indole (JWH-019) I 7019 1.00 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) I 7118 1.00 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) I 7203 1.00 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) I 6250 1.00 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) I 7398 1.00 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) I 7122 1.00 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4) I 7104 1.00 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) I 7081 1.00 2-(1-(4-fluorobenzyl)-1H -indazole-3-carboxamido)-3-methylbutanoate (FUB-AMB, MMB-FUBINACA) I 7021 1.00 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) I 7524 1.00 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine Hydrochloride (2C-P) I 7524 0.86 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) I 7509 1.00 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine Hydrochloride (2C-E) I 7509 0.85 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) I 7508 1.00 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine Hydrochloride (2C-D) I 7508 0.84 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) I 7521 1.00 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine Hydrochloride (2C-N) I 7521 0.86 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) I 7517 1.00 2-(2,5-Dimethoxyphenyl)ethanamine Hydrochloride (2C-H) I 7517 0.83 2-(4-Bromo-2,5-dimethoxyphenyl)-N -(2-methoxybenzyl)ethanamine (25B-NBOMe) I 7536 1.00 2-(4-Bromo-2,5-dimethoxyphenyl)-N -(2-methoxybenzyl)ethanamine Hydrochloride (25B-NBOMe) I 7536 0.91 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) I 7519 1.00 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine Hydrochloride (2C-C) I 7519 0.86 2-(4-Chloro-2,5-dimethoxyphenyl)-N -(2-methoxybenzyl)ethanamine (25C-NBOMe) I 7537 1.00 2-(4-Chloro-2,5-dimethoxyphenyl)-N -(2-methoxybenzyl)ethanamine Hydrochloride (25C-NBOMe) I 7537 0.90 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) I 7518 1.00 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine Hydrochloride (2C-I) I 7518 0.89 2-(4-Iodo-2,5-dimethoxyphenyl)-N -(2-methoxybenzyl)ethanamine (25I-NBOMe) I 7538 1.00 2-(4-Iodo-2,5-dimethoxyphenyl)-N -(2-methoxybenzyl)ethanamine Hydrochloride (25I-NBOMe) I 7538 0.92 2,5-Dimethoxy-4-ethylamphetamine (DOET) I 7399 1.00 2,5-Dimethoxy-4-ethylamphetamine Hydrochloride (DOET) I 7399 0.86 2,5-Dimethoxy-4-n -propylthiophenethylamine (2C-T-7) I 7348 1.00 2,5-Dimethoxy-4-n -propylthiophenethylamine Hydrochloride I 7348 0.88 2,5-Dimethoxyamphetamine I 7396 1.00 2,5-Dimethoxyamphetamine Hydrochloride I 7396 0.84 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) I 7385 1.00 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine Hydrochloride (2C-T-2) I 7385 0.87 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) I 7532 1.00 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine Hydrochloride (2C-T-4) I 7532 0.88 2-methoxy-N -(1-phenethylpiperidin-4-yl)-N -phenylacetamide (methoxyacetyl fentanyl) I 9825 1.00 2-methoxy-N -(1-phenethylpiperidin-4-yl)-N -phenylacetamide hydrochloride (methoxyacetyl fentanyl) I 9825 0.91 3,4,5-Trimethoxyamphetamine I 7390 1.00 3,4,5-Trimethoxyamphetamine Hydrochloride I 7390 0.86 3,4-dichloro-N -[(1-dimethylamino)cyclohexylmethyl]benzamide) (AH-7921) I 9551 1.00 3,4-dichloro-N -[(1-dimethylamino)cyclohexylmethyl]benzamide) Hydrochloride (AH-7921) I 9551 0.90 3,4-dichloro-N -[2-(dimethylamino)cyclohexyl]-N -methylbenzamide (U-47700) I 9547 1.00 3,4-Methylenedioxyamphetamine (MDA) I 7400 1.00 3,4-Methylenedioxyamphetamine Hydrochloride (MDA) I 7400 0.83 SCHEDULES I - V CONTROLLED SUBSTANCE CONVERSION FACTORS Drug Conversion Controlled Substance Schedule Code Factor 3,4-Methylenedioxymethamphetamine (MDMA) I 7405 1.00 3,4-Methylenedioxymethamphetamine Hydrochloride (MDMA) I 7405 0.84 3,4-Methylenedioxy-N -ethylamphetamine (MDEA) I 7404 1.00 3,4-Methylenedioxy-N -ethylamphetamine Hydrochloride (MDEA) I 7404 0.85 3,4-Methylenedioxy-N -methylcathinone (methylone) I 7540 1.00 3,4-Methylenedioxy-N -methylcathinone Hydrochloride (methylone) I 7540 0.85 3,4-Methylenedioxypyrovalerone (MDPV) I 7535 1.00 3,4-Methylenedioxypyrovalerone Hydrochloride (MDPV) I 7535 0.88 3-fluoro-N -methylcathinone (3-FMC) I 1233 1.00 3-fluoro-N -methylcathinone Hydrochloride (3-FMC) I 1233 0.83 3-Methylfentanyl I 9813 1.00 3-Methylfentanyl Hydrochloride I 9813 0.91 3-Methylthiofentanyl I 9833 1.00 3-Methylthiofentanyl Hydrochloride I 9833 0.91 3-Methylthiofentanyl Hydrochloride (1/2 H2O) I 9833 0.89 4-Anilino-N -phenethyl-4-piperidine (ANPP) II 8333 1.00 4-Anilino-N -phenethyl-4-piperidine Hydrochloride (ANPP) II 8333 0.88 4-Bromo-2,5-dimethoxyamphetamine (DOB) I 7391 1.00 4-Bromo-2,5-dimethoxyamphetamine Hydrochloride (DOB) I 7391 0.88 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) I 7392 1.00 4-Bromo-2,5-dimethoxyphenethylamine Hydrochloride (2C-B) I 7392 0.88 4'-Chloro-alpha -pyrrolidinovalerophenone I 7443 1.00 4'-Chloro-alpha -pyrrolidinovalerophenone hydrochloride I 7443 0.88 4-fluoro-N -methylcathinone (4-FMC) I 1238 1.00 4-fluoro-N -methylcathinone Hydrochloride (4-FMC) I 1238 0.83 4-Methoxyamphetamine I 7411 1.00 4-Methoxyamphetamine Hydrochloride I 7411 0.82 4-Methyl-2,5-dimethoxyamphetamine (STP or DOM) I 7395 1.00 4-Methyl-2,5-dimethoxyamphetamine Hydrochloride (STP or DOM) I 7395 0.85 4-Methyl-alpha -ethylaminopentiophenone I 7245 1.00 4-Methyl-alpha -ethylaminopentiophenone hydrochloride I 7245 0.86 4'-Methyl-alpha -pyrrolidinohexiophenone I 7446 1.00 4'-Methyl-alpha -pyrrolidinohexiophenone hydrochloride I 7446 0.88 4-methyl-alphapyrrolidinopropiophenone (4-MePPP) I 7498 1.00 4-methyl-alphapyrrolidinopropiophenone hydrochloride (4-MePPP) I 7498 0.86 4-Methylmethcathinone (mephedrone) I 1248 1.00 4-Methylmethcathinone Hydrochloride (mephedrone) I 1248 0.83 4-methyl-N -ethylcathinone (4-MEC) I 1249 1.00 4-methyl-N -ethylcathinone hydrochloride (4-MEC) I 1249 0.84 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497) I 7297 1.00 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497 C8-homolog) I 7298 1.00 5-Methoxy-3,4-methylenedioxyamphetamine I 7401 1.00 5-Methoxy-3,4-methylenedioxyamphetamine Hydrochloride I 7401 0.85 5-Methoxy-N ,N -diisopropyltryptamine (5-MeO-DIPT) I 7439 1.00 5-Methoxy-N ,N -diisopropyltryptamine Hydrochloride I 7439 0.88 5-Methoxy-N ,N -dimethyltryptamine I 7431 1.00 5-Methoxy-N ,N -dimethyltryptamine Hydrochloride I 7431 0.86 Acetorphine I 9319 1.00 Acetorphine Hydrochloride I 9319 0.93 Acetyl-alpha -methylfentanyl I 9815 1.00 Acetyldihydrocodeine I 9051 1.00 Acetyldihydrocodeine Hydrochloride I 9051 0.90 Acetylmethadol I 9601 1.00 Acetylmethadol Hydrochloride I 9601 0.91 Alfaxalone IV 2731 1.00 Alfentanil II 9737 1.00 Alfentanil Hydrochloride II 9737 0.92 Alfentanil Hydrochloride (H2O) II 9737 0.88 Allylprodine I 9602 1.00 Allylprodine Hydrochloride I 9602 0.89 Alphacetylmethadol I 9603 1.00 Alphacetylmethadol Hydrochloride I 9603 0.91 alpha -Ethyltryptamine I 7249 1.00 alpha -Ethyltryptamine Acetate I 7249 0.76 alpha -Ethyltryptamine Hydrochloride I 7249 0.84 SCHEDULES I - V CONTROLLED SUBSTANCE CONVERSION FACTORS Drug Conversion Controlled Substance Schedule Code Factor Alphameprodine I 9604 1.00 Alphamethadol I 9605 1.00 alpha -Methylfentanyl I 9814 1.00 alpha -Methylfentanyl Hydrochloride I 9814 0.91 alpha -Methylthiofentanyl I 9832 1.00 alpha -Methylthiofentanyl Hydrochloride I 9832 0.91 alpha -Methyltryptamine (AMT) I 7432 1.00 alpha -Methyltryptamine Hydrochloride I 7432 0.83 Alphaprodine II 9010 1.00 Alphaprodine Hydrochloride II 9010 0.88 alpha -Pyrrolidinobutiophenone (α-PBP) I 7546 1.00 alpha -Pyrrolidinobutiophenone hydrochloride (α-PBP) I 7546 0.86 alpha -Pyrrolidinoheptaphenone I 7548 1.00 alpha -Pyrrolidinoheptaphenone hydrochloride I 7548 0.88 alpha -Pyrrolidinohexanophenone I 7544 1.00 alpha -Pyrrolidinohexanophenone hydrochloride I 7544 0.87 alpha -Pyrrolidinopentiophenone (α-PVP) I 7545 1.00 alpha -Pyrrolidinopentiophenone hydrochloride (α-PVP) I 7545 0.86 Alprazolam IV 2882 1.00 Aminorex I 1585 1.00 Aminorex Fumarate I 1585 0.58 Amobarbital II 2125 1.00 Amobarbital Sodium II 2125 0.91 Amphetamine II 1100 1.00 Amphetamine Adipate II 1100 0.48 Amphetamine Aspartate II 1100 0.50 Amphetamine Aspartate (H2O) II 1100 0.47 Amphetamine Hydrochloride
Load more

Recommended publications
  • Analysis of Benzylpiperazine-Like Compounds Hiroyuki Inoue 1
    鑑識科学，9(2)，165―184(2004) 165 ―Technical Note― Analysis of Benzylpiperazine-like Compounds Hiroyuki Inoue1,YukoT.Iwata1, Tatsuyuki Kanamori1, Hajime Miyaguchi1, Kenji Tsujikawa1, Kenji Kuwayama1, Hiroe Tsutsumi2, Munehiro Katagi2, Hitoshi Tsuchihashi2 and Tohru Kishi1 National Research Institute of Police Science 631, Kashiwanoha, Kashiwa, Chiba 2770882, Japan1 Forensic Science Laboratory, Osaka Prefectural Police H. Q. 1318, Hommachi, Chuo-ku, Osaka, Osaka 5410053, Japan2 (Received 6 January 2004; accepted 6 March 2004) 1-Benzylpiperazine (BZP) and 1-(3-tri‰uoromethylphenyl)piperazine, newly controlled as narcotics in Japan on 2003, and their analogues were analyzed. The analytical data with color test, thin layer chromatography (TLC), infrared spectroscopy (IR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) are presented. The BZP-like compounds were less sensitive to Simon's reagent than amphetamine type stimulants on spot plates. Using on-site screening kit based on Simon's test (X-Checker), BZP indicated almost the same result as methamphetamine. For TLC, the solvent system, methanol －25 aqueous ammonia (100 : 1.5), was the best among the systems examined. Iodoplatinate reagent was the most sensitive one to detect BZP. The IR spectra showed su‹cient diŠerences to make identiˆcation. Trimethylsilylation was the most appropriate choice for the GC/MS analysis of BZP-like compounds in terms of the peak shapes, separation and stability (using a J&W DB-5MS column). In LC/MS analysis, the gradient elution (10 mM formic acid and acetonitrile) using a Waters Symmetry Shield C18 column achieved discrimination of isomers except for 1-(2-‰uorophenyl) piperazine and 1-(4-‰uorophenyl)piperazine.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • KHAT Latest Revision: June 11, 2005
    KHAT Latest Revision: June 11, 2005 O CH3 NH2 Cathinone OH CH3 NH2 Cathine N CH3 H3C N 3,6-dimethyl-2,5-diphenylpyrazine (dimer of Cathinone) 1. SYNONYMS CFR: Cathinone Cathine CAS #: Cathinone Hydrochloride: 71031-15-7 Cathine Hydrochloride: 2153-98-2 Cathine Base: 492-39-7 Other Names: Catha edulis Kat Mutsawhari Mutsawari Mdimamadzi Musitate Mirungi Miraa Ol meraa Tumayot Liruti Ikwa Arabian Tea 2. CHEMICAL AND PHYSICAL DATA Khat is used as a stimulant or as a medicine in parts of Africa and the Arabian Peninsula. The plant is thought to have been in cultivation before the coffee plant; historical references date the use of the plant to the fourteenth century. Peter Forsskal, a physician and botanist, collected khat specimens in an expedition organized by the King of Denmark in the eighteenth century. Forsskal assigned the name Catha edulis to the plant. The effects produced by the drug include excitation, hypersensitivity, anorexia, insomnia, euphoria, increased respiration, and hyperthermia. These effects closely parallel the effects of d-amphetamine. Khat is a bush or tree that grows naturally in the humid mountainous regions (elevations of 5000 to 6500 feet) of East and South Africa. The trees can grow naturally to over 60 ft; however, cultivated khat trees are pruned and their height to kept to approximately 16 feet. Khat also grows to a height of 3 feet as a small bush in arid regions. Like opium, the alkaloid content of khat will vary with the soil, climatic conditions, and cultivation. Khat belongs to the genus Catha edulis. It is recognized that the genus consists of only one species; however, the plant exhibits extreme polymorphism.
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Acquired Synaesthesia Following 2C-B Use
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Greenwich Academic Literature Archive Acquired synaesthesia following 2C-B use • Authors • Authors and affiliations • Steliana Yanakieva (Department of Psychology, Goldsmiths, University of London) • David P. Luke (Department of Psychology, Social Work and Counselling, University of Greenwich) • Ashok Jansari (Department of Psychology, Goldsmiths, University of London) • Devin B. Terhune (Department of Psychology, Goldsmiths, University of London) Letter to Editor This study was previously presented at Bridging senses: New developments in synesthesia (Royal Society, London, UK, 22–23 October 2018). Psychedelic drugs reliably trigger experiences that closely resemble synaesthesia (Luke and Terhune 2013), a condition in which inducer stimuli will reliably and automatically elicit atypical concurrent experiences (Ward 2013). These transient episodes are considered controversial because they do not meet behavioural diagnostic criteria for developmental synaesthesia (Terhune et al. 2016). However, if these behavioural markers are attributable to the consolidation of synaesthetic associations over time (Terhune et al. 2016), they should be observed in cases of acquired synaesthesia. Here we report a case of drug-induced acquired synaesthesia (LW) that meets standard diagnostic criteria for developmental synaesthesia. LW is a 29-year-old male who reports continuously experiencing multiple forms of synaesthesia for over 7 years since ingesting approximately 70–150 mg of 2,5-dimethoxy-4- bromophenethylamine (2C-B) (Papaseit et al. 2018), which greatly exceeds the normal dosage (12–24 mg) (Shulgin and Shulgin 1990) (see Supplementary Materials). LW was contrasted against 10 non-synaesthete healthy controls, all of whom provided informed written consent.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • (Methadone Hydrochloride Oral Concentrate USP) and Methadose
    NDA 17-116/S-021 Page 3 Methadose™ Oral Concentrate (methadone hydrochloride oral concentrate USP) and Methadose™ Sugar-Free Oral Concentrate (methadone hydrochloride oral concentrate USP) dye-free, sugar-free, unflavored CII Rx only FOR ORAL USE ONLY Deaths have been reported during initiation of methadone treatment for opioid dependence. In some cases, drug interactions with other drugs, both licit and illicit, have been suspected. However, in other cases, deaths appear to have occurred due to the respiratory or cardiac effects of methadone and too-rapid titration without appreciation for the accumulation of methadone over time. It is critical to understand the pharmacokinetics of methadone and to exercise vigilance during treatment initiation and dose titration (see DOSAGE AND ADMINISTRATION). Patients must also be strongly cautioned against self- medicating with CNS depressants during initiation of methadone treatment. Respiratory depression is the chief hazard associated with methadone hydrochloride administration. Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects, particularly in the early dosing period. These characteristics can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration. Cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, NDA
    [Show full text]
  • Misperceptions About Contraceptives Persist
    30 Women’s Health FAMILY P RACTICE N EWS • September 1, 2008 Misperceptions About Contraceptives Persist BY DOUG BRUNK trauterine device use; 50% thought IUD (SOGC). There may be inadequate in- Oral contraceptives are also safe in women San Diego Bureau failure was a major risk; and fewer than struction with regard to contraception in older than age 35 if they are healthy non- one-third would recommend an IUD as an physician-training programs, she said. smokers, and in women with systemic lu- C ALGARY, ALTA. — Physicians may option for nulliparous women, for post- “Not everybody does IUD insertions, sub- pus erythematosus provided they have no have a surprising number of misconcep- coital contraception, for women with fi- dermal progestin implant, or vasectomy.” antiphospholipid antibodies, vascular dis- tions about birth control, according to re- broids, or for women who had pelvic in- Other barriers to effective contraceptive ease, or nephritis. cent responses to a survey by 96 family flammatory disease within the last year use include exaggerated concerns about Another common exaggerated concern physicians in Kingston, Ont. (Can. Fam. Physician 2008;54:560-6). potential side effects. For example, women is that the use of oral and transdermal Contrary to evidence in the medical lit- “Only 41% of these physicians inserted with diabetes may use oral contraceptives patch contraceptives cause weight gain. erature, more than 60% of respondents IUDs,” Dr. Amanda Black said at the an- if they have no end-organ damage, said Dr. However, a recent Cochrane systematic re- thought pelvic inflammatory disease and nual meeting of the Society of Obstetri- Black of the division of general obstetrics view of randomized, controlled data con- ectopic pregnancy were major risks of in- cians and Gynaecologists of Canada and gynecology at the Ottawa Hospital.
    [Show full text]